

Angelo Antonini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7679200/publications.pdf>

Version: 2024-02-01

603
papers

34,963
citations

2975

93
h-index

6836

155
g-index

623
all docs

623
docs citations

623
times ranked

25088
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
2	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	3.9	1,171
3	Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2007, 356, 39-46.	27.0	824
4	Requirement for subplate neurons in the formation of thalamocortical connections. <i>Nature</i> , 1990, 347, 179-181.	27.8	561
5	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology</i> , The, 2014, 13, 141-149.	10.2	547
6	Rapid remodeling of axonal arbors in the visual cortex. <i>Science</i> , 1993, 260, 1819-1821.	12.6	546
7	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.	21.4	502
8	<sc>EFNS</sc>/<sc>MDS</sc>â€<sc>ES</sc> recommendations for the diagnosis of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.	3.3	460
9	miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. <i>Cell Death and Differentiation</i> , 2011, 18, 1628-1639.	11.2	399
10	Patterns of regional brain activation associated with different forms of motor learning. <i>Brain Research</i> , 2000, 871, 127-145.	2.2	344
11	Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005, 65, 87-95.	1.1	323
12	Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). <i>European Neuropsychopharmacology</i> , 1997, 7, 9-24.	0.7	320
13	Parkinsonâ€™s disease: The non-motor issues. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 717-723.	2.2	313
14	Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. <i>Brain</i> , 1996, 119, 2085-2095.	7.6	312
15	Functional brain networks in DYT1 dystonia. <i>Annals of Neurology</i> , 1998, 44, 303-312.	5.3	302
16	Anatomical Correlates of Functional Plasticity in Mouse Visual Cortex. <i>Journal of Neuroscience</i> , 1999, 19, 4388-4406.	3.6	302
17	Pramipexole versus sertraline in the treatment of depression in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2006, 253, 601-607.	3.6	250
18	Development of individual geniculocortical arbors in cat striate cortex and effects of binocular impulse blockade. <i>Journal of Neuroscience</i> , 1993, 13, 3549-3573.	3.6	246

#	ARTICLE	IF	CITATIONS
19	Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. <i>Movement Disorders</i> , 2007, 22, 1145-1149.	3.9	241
20	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , 2009, 24, 1468-1474.	3.9	233
21	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. <i>Lancet Neurology</i> , The, 2007, 6, 826-829.	10.2	231
22	Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. <i>NeuroImage</i> , 2011, 54, 1244-1253.	4.2	216
23	Long-term changes of striatal dopamine D ₂ Receptors in patients with Parkinson's disease: A study with positron emission tomography and [¹¹ C]Raclopride. <i>Movement Disorders</i> , 1997, 12, 33-38.	3.9	215
24	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.	3.6	211
25	Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Brain</i> , 1997, 120, 2187-2195.	7.6	209
26	Pain as a Nonmotor Symptom of Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1191-4.	4.5	208
27	Role of DAT-SPECT in the diagnostic work up of Parkinsonism. <i>Movement Disorders</i> , 2007, 22, 1229-1238.	3.9	206
28	Euro-observational study of amphetamine and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 510-516.	3.9	203
29	α ₂ and α ₁ Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines. <i>Experimental Cell Research</i> , 1997, 236, 76-85.	2.6	201
30	Levodopa in the treatment of Parkinson's disease: an old drug still going strong. <i>Clinical Interventions in Aging</i> , 2010, 5, 229.	2.9	194
31	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	3.9	193
32	Outcome of Parkinson's Disease Patients Affected by COVID-19. <i>Movement Disorders</i> , 2020, 35, 905-908.	3.9	192
33	Dynamic functional connectivity changes associated with dementia in Parkinson's disease. <i>Brain</i> , 2019, 142, 2860-2872.	7.6	190
34	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015, 30, 1623-1631.	3.9	189
35	[¹¹ C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease. <i>Neurology</i> , 1994, 44, 1325-1325.	1.1	188
36	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	3.6	188

#	ARTICLE	IF	CITATIONS
37	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	3.9	179
38	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , 2005, 42, e65-e65.	3.2	178
39	Positron emission tomographic studies in restless legs syndrome. <i>Movement Disorders</i> , 1999, 14, 141-145.	3.9	177
40	Effect of Age on D2 Dopamine Receptors in Normal Human Brain Measured by Positron Emission Tomography and 11C-Raclopride. <i>Archives of Neurology</i> , 1993, 50, 474-480.	4.5	170
41	Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 1183-1190.	4.5	169
42	A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. <i>Lancet Neurology</i> , 2009, 8, 929-937.	10.2	169
43	T ₂ relaxation time in patients with Parkinson's disease. <i>Neurology</i> , 1993, 43, 697-697.	1.1	162
44	The metabolic topography of essential blepharospasm. <i>Neurology</i> , 2000, 55, 673-677.	1.1	161
45	The metabolic anatomy of Tourette's syndrome. <i>Neurology</i> , 1997, 48, 927-933.	1.1	160
46	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	2.2	156
47	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	2.8	152
48	Regulation of ER-mitochondria contacts by Parkin via Mfn2. <i>Pharmacological Research</i> , 2018, 138, 43-56.	7.1	152
49	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. <i>Current Medical Research and Opinion</i> , 2018, 34, 2063-2073.	1.9	152
50	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 156.	3.7	150
51	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	2.2	149
52	123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Neurological Sciences</i> , 2003, 24, 149-150.	1.9	146
53	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009, 24, 826-832.	3.9	146
54	Storage characteristics of cathodes for Li-ion batteries. <i>Electrochimica Acta</i> , 1996, 41, 2683-2689.	5.2	145

#	ARTICLE	IF	CITATIONS
55	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	3.6	140
56	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	3.9	139
57	Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. <i>Journal of Nuclear Medicine</i> , 2001, 42, 1591-5.	5.0	139
58	Mesial versus lateral temporal lobe epilepsy. <i>Neurology</i> , 1993, 43, 79-79.	1.1	138
59	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. <i>Neurobiology of Disease</i> , 2010, 39, 98-104.	4.4	136
60	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. <i>Brain</i> , 2001, 124, 1601-1609.	7.6	133
61	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 411-415.	3.9	131
62	Dopamine transporter imaging with fluorine-18-FPCIT and PET. <i>Journal of Nuclear Medicine</i> , 1998, 39, 1521-30.	5.0	131
63	Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 450-453.	1.9	130
64	Ultrastructural Evidence for Synaptic Interactions between Thalamocortical Axons and Subplate Neurons. <i>European Journal of Neuroscience</i> , 1994, 6, 1729-1742.	2.6	128
65	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013, 260, 2701-2714.	3.6	128
66	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1604-11.	4.5	127
67	Plasticity of geniculocortical afferents following brief or prolonged monocular occlusion in the cat. <i>Journal of Neurophysiology</i> , 1996, 36, 64-82.		126
68	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.	3.9	126
69	Medical and surgical management of advanced Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 900-908.	3.9	124
70	Tuning AlAs-GaAs band discontinuities and the role of Si-induced local interface dipoles. <i>Physical Review B</i> , 1991, 43, 2450-2453.	3.2	123
71	Validation of the Italian version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013, 34, 683-687.	1.9	123
72	Early Detection of Wearing off in Parkinson disease: The DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 204-211.	2.2	121

#	ARTICLE	IF	CITATIONS
73	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
74	[11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. <i>Annals of Neurology</i> , 1998, 43, 253-255.	5.3	120
75	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. <i>Npj Parkinson's Disease</i> , 2020, 6, 18.	5.3	120
76	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 317-324.	1.9	119
77	Metabolic correlates of pallidal neuronal activity in Parkinson's disease. <i>Brain</i> , 1997, 120, 1315-1324.	7.6	118
78	Cerebral Glucose Metabolism in Women With Panic Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 1178-1183.	7.2	118
79	Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 231-235.	2.2	118
80	Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 57-64.	2.8	117
81	Relation Between Putative Transmitter Phenotypes and Connectivity of Subplate Neurons During Cerebral Cortical Development. <i>European Journal of Neuroscience</i> , 1990, 2, 744-761.	2.6	115
82	Emergence of ocular dominance columns in cat visual cortex by 2 weeks of age. <i>Journal of Comparative Neurology</i> , 2001, 430, 235-249.	1.6	113
83	A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. <i>Journal of Neurology</i> , 2011, 258, 579-585.	3.6	113
84	Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 660-665.	2.2	112
85	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. <i>Movement Disorders</i> , 2011, 26, 225-233.	3.9	109
86	Tolerability of paroxetine in Parkinson's disease: A prospective study. <i>Movement Disorders</i> , 2000, 15, 986-989.	3.9	107
87	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001, 49, 155-164.	5.3	107
88	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. <i>Journal of Parkinson's Disease</i> , 2011, 1, 197-203.	2.8	107
89	The metabolic anatomy of tremor in Parkinson's disease. <i>Neurology</i> , 1998, 51, 803-810.	1.1	106
90	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 410-419.	2.2	106

#	ARTICLE	IF	CITATIONS
91	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. <i>Movement Disorders</i> , 1998, 13, 268-274.	3.9	105
92	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 431-438.	2.8	102
93	Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. <i>Movement Disorders</i> , 2006, 21, 1119-1122.	3.9	101
94	Wearing off scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.	3.9	101
95	Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 501-507.	2.2	99
96	MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. <i>American Journal of Neuroradiology</i> , 2004, 25, 927-32.	2.4	97
97	Cognitive decline in Parkinson's disease: the complex picture. <i>Npj Parkinson's Disease</i> , 2016, 2, 16018.	5.3	96
98	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. <i>PLoS ONE</i> , 2013, 8, e57221.	2.5	95
99	Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 244-246.	1.4	93
100	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 287-291.	2.2	93
101	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
102	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.	3.9	92
103	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017, 32, 510-525.	3.9	92
104	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 361-372.	1.5	91
105	Reproducibility of regional metabolic covariance patterns: comparison of four populations. <i>Journal of Nuclear Medicine</i> , 1999, 40, 1264-9.	5.0	91
106	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	7.6	90
107	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020, 66, 101714.	11.6	90
108	Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 14, 734-740.	2.7	89

#	ARTICLE	IF	CITATIONS
109	Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. <i>Movement Disorders</i> , 2016, 31, 530-537.	3.9	88
110	Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2002, 17, 1265-1270.	3.9	86
111	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.	1.6	86
112	Stridor in multiple system atrophy. <i>Neurology</i> , 2019, 93, 630-639.	1.1	86
113	Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 289-295.	2.2	85
114	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1.	2.2	85
115	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.	2.5	84
116	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.	4.5	83
117	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 688-695.	3.9	83
118	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 76-82.	1.9	82
119	Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 394-399.	2.2	82
120	Doped Li-Mn Spinels: Physical/Chemical Characteristics and Electrochemical Performance in Li Batteries. <i>Chemistry of Materials</i> , 1997, 9, 1443-1450.	6.7	81
121	Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 644-649.	2.2	81
122	Radiosynthesis of [18F] N-3-fluoropropyl-2- ¹² C-carbomethoxy-3- ¹² C-(4-iodophenyl) nortropine and the first human study with positron emission tomography. <i>Nuclear Medicine and Biology</i> , 1996, 23, 999-1004.	0.6	80
123	Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson's Disease. <i>Drug Safety</i> , 2009, 32, 475-488.	3.2	80
124	Imaging essential tremor. <i>Movement Disorders</i> , 2010, 25, 679-686.	3.9	80
125	Pioneer Neurons and Target Selection in Cerebral Cortical Development. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1990, 55, 469-480.	1.1	80
126	Cerebral glucose metabolism in patients with spasmodic torticollis. <i>Movement Disorders</i> , 1997, 12, 704-708.	3.9	78

#	ARTICLE	IF	CITATIONS
127	The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. <i>Neurological Sciences</i> , 2001, 22, 47-48.	1.9	78
128	Hydrocarbon exposure and Parkinson's disease. <i>Neurology</i> , 2000, 55, 667-673.	1.1	77
129	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 528-531.	2.2	77
130	Surgical, Medical, and Hardware Adverse Events in a Series of 141 Patients Undergoing Subthalamic Deep Brain Stimulation for Parkinson Disease. <i>World Neurosurgery</i> , 2010, 73, 338-344.	1.3	77
131	Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 859-867.	2.8	76
132	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1231-1235.	2.2	76
133	Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , 2015, 30, 114-120.	3.9	76
134	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.	3.3	76
135	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , 2013, 120, 613-618.	2.8	75
136	A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015, 22, 1184-1191.	3.3	75
137	Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. <i>Neurology</i> , 1994, 44, 2125-2125.	1.1	75
138	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.	2.5	74
139	Dopamine D2 Receptors in Normal Human Brain: Effect of Age Measured by Positron Emission Tomography (PET) and [11C]-Raclopride. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 81-85.	3.8	73
140	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 27-31.	2.2	73
141	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
142	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. <i>Journal of the Neurological Sciences</i> , 2011, 310, 64-69.	0.6	70
143	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1237-1247.	3.9	70
144	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 14.	5.3	70

#	ARTICLE	IF	CITATIONS
145	Striatal dopamine transporter abnormalities in patients with essential tremor. <i>Nuclear Medicine Communications</i> , 2008, 29, 349-353.	1.1	69
146	Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients. <i>PLoS ONE</i> , 2014, 9, e85595.	2.5	69
147	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 421-430.	3.9	69
148	<sc>USP</sc> 14 inhibition corrects an <i>in vivo</i> model of impaired mitophagy. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	69
149	Disease progression in Parkinson subtypes: the PPMI dataset. <i>Neurological Sciences</i> , 2018, 39, 1971-1976.	1.9	67
150	Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. <i>Human Mutation</i> , 2007, 28, 98-98.	2.5	66
151	Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms – results of a double-blind, randomized, placebo-controlled trial. <i>European Journal of Neurology</i> , 2015, 22, 1400-1407.	3.3	66
152	PD_Manager: an mHealth platform for Parkinson's disease patient management. <i>Healthcare Technology Letters</i> , 2017, 4, 102-108.	3.3	66
153	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. <i>European Radiology</i> , 2017, 27, 2665-2675.	4.5	66
154	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018, 25, 917.	3.3	66
155	Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. <i>Movement Disorders</i> , 2017, 32, 1557-1565.	3.9	65
156	Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S97-S100.	2.2	64
157	Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1329-1334.	2.2	64
158	Benzodiazepine receptor binding in Huntington's disease: [¹¹ C]Flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , 2000, 47, 644-648.	5.3	62
159	Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 253-259.	3.6	62
160	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 290-294.	2.2	61
161	Clinical and [¹²³ I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>Journal of Neurology</i> , 2009, 256, 910-915.	3.6	61
162	Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 397-399.	2.2	61

#	ARTICLE	IF	CITATIONS
163	Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2016, 123, 1435-1442.	2.8	61
164	Morphology of Single Geniculocortical Afferents and Functional Recovery of the Visual Cortex after Reverse Monocular Deprivation in the Kitten. <i>Journal of Neuroscience</i> , 1998, 18, 9896-9909.	3.6	60
165	Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 424-431.	3.9	60
166	Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 119-129.	5.9	60
167	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 10-16.	2.2	60
168	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.	0.8	60
169	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , 2007, 18, 1499-1502.	1.2	59
170	Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , 2013, 120, 1553-1558.	2.8	59
171	The "Gender Factor" in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study. <i>Scientific World Journal</i> , The, 2015, 2015, 1-10.	2.1	59
172	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.	2.2	58
173	Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. <i>Neurological Sciences</i> , 2001, 22, 45-46.	1.9	57
174	Anatomical and functional correlates of persistent pain in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1854-1864.	3.9	57
175	Preoperative indicators of clinical outcome following stereotaxic pallidotomy. <i>Neurology</i> , 1997, 49, 1083-1090.	1.1	56
176	Factors Affecting the Stabilization of Mn Spinel Capacity upon Staring and Cycling at High Temperatures. <i>Journal of the Electrochemical Society</i> , 1998, 145, 2726-2732.	2.9	55
177	Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. <i>Brain Stimulation</i> , 2015, 8, 1223-1225.	1.6	55
178	First results from the high energy resolution photoemission beam line at ELETTRA. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 1995, 364, 374-379.	1.6	54
179	CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE: A FOLLOW-UP OF TWO YEARS. <i>Archives of Gerontology and Geriatrics</i> , 2004, 38, 291-296.	3.0	53
180	Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [123I]β-CIT SPECT study. <i>Journal of Neural Transmission</i> , 2008, 115, 721-729.	2.8	53

#	ARTICLE	IF	CITATIONS
181	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. <i>Movement Disorders</i> , 2009, 24, 1028-1033.	3.9	53
182	Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 281-294.	2.4	53
183	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018, 11, 904-912.	1.6	53
184	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. <i>Journal of Neurology</i> , 2018, 265, 1124-1137.	3.6	52
185	An overnight switch to ropinirole therapy in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 1999, 106, 925-929.	2.8	51
186	Cost-effectiveness of ¹²³ I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. <i>Movement Disorders</i> , 2008, 23, 2202-2209.	3.9	51
187	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 205-207.	0.7	51
188	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016, 23, 1556-1565.	3.3	51
189	Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum. <i>Movement Disorders</i> , 2021, 36, 1287-1289.	3.9	51
190	Brain SPECT imaging in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2005, 112, 1635-1645.	2.8	50
191	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 432.	2.4	50
192	Physiological organization of callosal connections of a visual lateral suprasylvian cortical area in the cat. <i>Journal of Neurophysiology</i> , 1983, 49, 902-921.	1.8	49
193	Thin Section MR Study of the Basal Ganglia in the Differential Diagnosis Between Striatonigral Degeneration and Parkinson Disease. <i>Journal of Computer Assisted Tomography</i> , 2002, 26, 266-271.	0.9	49
194	Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , 2010, 257, 247-252.	3.6	49
195	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.	2.1	49
196	European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. <i>Movement Disorders</i> , 2022, 37, 1360-1374.	3.9	49
197	Role of Pramipexole in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 829-841.	5.9	48
198	Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 627-633.	2.8	48

#	ARTICLE	IF	CITATIONS
199	Anatomy and Connectivity of the Subthalamic Nucleus in Humans and Non-human Primates. <i>Frontiers in Neuroanatomy</i> , 2020, 14, 13.	1.7	48
200	Importance of corpus callosum for visual receptive fields of single neurons in cat superior colliculus. <i>Journal of Neurophysiology</i> , 1979, 42, 137-152.	1.8	47
201	[¹²³ I]FP-CIT SPET imaging in drug-induced Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1825-1829.	3.9	47
202	Anatomical Correlates of Cognitive Functions in Early Parkinson's Disease Patients. <i>PLoS ONE</i> , 2013, 8, e64222.	2.5	47
203	Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2019, 34, 816-819.	3.9	47
204	Extradural motor cortex stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 111-114.	3.9	46
205	Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. <i>Movement Disorders</i> , 2007, 22, 275-278.	3.9	46
206	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	2.8	46
207	Reproducibility of Regional Metabolic Covariance Patterns: Comparison of Four Populations. , 1998, , 247-252.		46
208	Increased cerebral iron uptake in Wilson's disease: a ⁵² Fe-citrate PET study. <i>Journal of Nuclear Medicine</i> , 2000, 41, 781-7.	5.0	46
209	AlAs-GaAs heterojunction engineering by means of group-IV elemental interface layers. <i>Physical Review B</i> , 1992, 45, 4528-4531.	3.2	45
210	Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 576-581.	2.2	45
211	Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. <i>World Neurosurgery</i> , 2017, 99, 41-46.	1.3	45
212	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017, 7, 533-543.	2.8	45
213	Nutritional habits, risk, and progression of Parkinson disease. <i>Journal of Neurology</i> , 2018, 265, 12-23.	3.6	45
214	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	1.5	45
215	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of organic neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	3.3	45
216	Structure and local dipole of Si interface layers in AlAs-GaAs heterostructures. <i>Physical Review B</i> , 1992, 46, 6834-6845.	3.2	44

#	ARTICLE	IF	CITATIONS
217	n-Hexane-induced parkinsonism: Pathogenetic hypotheses. <i>Movement Disorders</i> , 1995, 10, 279-282.	3.9	44
218	Dopa-responsive pseudo-orthostatic tremor in parkinsonism. <i>Movement Disorders</i> , 2007, 22, 1652-1656.	3.9	44
219	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.	2.2	44
220	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 37-43.	2.2	44
221	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 491-501.	2.8	44
222	Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: Case report. <i>Movement Disorders</i> , 2006, 21, 270-273.	3.9	43
223	Increased striatal glucose consumption in sydenham's chorea. <i>Movement Disorders</i> , 1993, 8, 437-444.	3.9	42
224	Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 326-333.	2.2	42
225	Reasons for hospitalization in Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 488-492.	2.2	42
226	Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. <i>Journal of Neurology</i> , 2019, 266, 2164-2176.	3.6	42
227	Epilepsia partialis continua studied by PET. <i>Epilepsy Research</i> , 1991, 9, 44-48.	1.6	41
228	Pramipexole-treated Parkinson's disease during pregnancy. <i>Movement Disorders</i> , 2004, 19, 1114-1115.	3.9	41
229	Tailoring of silicon crystals for relativistic-particle channeling. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2005, 234, 40-46.	1.4	41
230	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. <i>Movement Disorders</i> , 2006, 21, 1144-1147.	3.9	41
231	Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. <i>European Journal of Neurology</i> , 2016, 23, 190-195.	3.3	41
232	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on "Off"-time in Patients with Advanced Parkinson's Disease: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 2854-2890.	2.9	41
233	Wild-Type p53 Gene Transfer Inhibits Invasion and Reduces Matrix Metalloproteinase-2 Levels in p53-Mutated Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 1188-1194.	0.7	40
234	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. <i>Neurological Sciences</i> , 2002, 23, s59-s60.	1.9	40

#	ARTICLE	IF	CITATIONS
235	Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. <i>Neurological Sciences</i> , 2006, 27, 397-401.	1.9	40
236	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 140-146.	1.4	40
237	Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. <i>Neurological Sciences</i> , 2010, 31, 35-40.	1.9	40
238	Spinal Cord Stimulation for the Treatment of Sensory Symptoms in Advanced Parkinson's Disease. <i>Neuromodulation</i> , 2013, 16, 276-279.	0.8	40
239	Buckwheat achenes antioxidant profile modulates <i>Aspergillus flavus</i> growth and aflatoxin production. <i>International Journal of Food Microbiology</i> , 2014, 189, 1-10.	4.7	40
240	The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. <i>Journal of Neural Transmission</i> , 2016, 123, 241-250.	2.8	40
241	Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. <i>Movement Disorders</i> , 2021, 36, 1781-1791.	3.9	40
242	Photoemission from atomic and molecular adsorbates on Rh(100). <i>Surface Science</i> , 1996, 347, 53-62.	1.9	39
243	Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, 174-175.	1.9	39
244	The effect of doping LiMn ₂ O ₄ spinel on its use as a cathode in Li-ion batteries: neutron diffraction and electrochemical studies. <i>Journal of Physics and Chemistry of Solids</i> , 2004, 65, 29-37.	4.0	39
245	Continuous dopaminergic stimulation: From theory to clinical practice. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S24-S28.	2.2	39
246	The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> , 2010, 257, 1882-1889.	3.6	39
247	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018, 33, 99-107.	3.9	39
248	Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. <i>Nuclear Medicine Communications</i> , 1994, 15, 806-813.	1.1	38
249	Temporal lobe epilepsy: Correlation of proton magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. <i>Magnetic Resonance in Medicine</i> , 1997, 37, 18-23.	3.0	38
250	Multilayer SiC for thermal protection system of space vehicles with decreased thermal conductivity through the thickness. <i>Journal of the European Ceramic Society</i> , 2010, 30, 1833-1840.	5.7	38
251	Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 840-860.	0.5	38
252	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.	3.9	38

#	ARTICLE	IF	CITATIONS
253	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 128.	3.8	38
254	Callosum-dependent binocular interactions in the lateral suprasylvian area of Siamese cats which lack binocular neurons in areas 17 and 18. <i>Brain Research</i> , 1980, 197, 230-235.	2.2	37
255	The <scp>PRIAMO</scp> study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 788-795.	3.3	37
256	Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson's disease: a randomized controlled pilot study. <i>Clinical Rehabilitation</i> , 2017, 31, 1107-1115.	2.2	37
257	Validation of the Movement Disorder Society Criteria for the Diagnosis of Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
258	Indirect, across-the-midline retinotectal projections and representation of ipsilateral visual field in superior colliculus of the cat. <i>Journal of Neurophysiology</i> , 1978, 41, 285-304.	1.8	36
259	Learning and interhemispheric transfer of visual pattern discriminations following unilateral suprasylvian lesions in split-chiasm cats. <i>Experimental Brain Research</i> , 1979, 34, 551-74.	1.5	36
260	Binocularity in the visual cortex of the adult cat does not depend on the integrity of the corpus callosum. <i>Behavioural Brain Research</i> , 1984, 13, 183-192.	2.2	36
261	PET and SPECT functional imaging in Parkinson's disease. <i>Sleep Medicine</i> , 2004, 5, 201-206.	1.6	36
262	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , 2005, 65, 1971-1973.	1.1	36
263	±-Synuclein multiplication analysis in Italian familial Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 228-231.	2.2	36
264	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018, 11, 867-874.	1.6	36
265	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 1697-1705.	1.6	36
266	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.	1.9	36
267	The contribution of the corpus callosum to receptive fields in the lateral suprasylvian visual areas of the cat. <i>Behavioural Brain Research</i> , 1982, 4, 155-176.	2.2	35
268	Visual and somatosensory integration in the anterior ectosylvian cortex of the cat. <i>Brain Research</i> , 1987, 410, 21-31.	2.2	35
269	A morphological study of SEI film on graphite electrodes. <i>Journal of Power Sources</i> , 2001, 97-98, 146-150.	7.8	35
270	Anatomical identification of active contacts in subthalamic deep brain stimulation. <i>World Neurosurgery</i> , 2007, 67, 140-146.	1.3	35

#	ARTICLE	IF	CITATIONS
271	Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. <i>Neurogenetics</i> , 2007, 8, 103-109.	1.4	35
272	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. <i>Movement Disorders</i> , 2008, 23, 2049-2054.	3.9	35
273	Effect of sensory disuse on geniculate afferents to cat visual cortex. <i>Visual Neuroscience</i> , 1998, 15, 401-9.	1.0	34
274	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.	2.2	33
275	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.	2.2	33
276	Application of the α -syn ⁵⁻²⁻¹ ™ screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , 2020, 10, 309-323.	2.2	33
277	Striatal dopamine D ₂ receptors in patients with narcolepsy measured with PET and [¹¹ C]raclopride. <i>Neurology</i> , 1994, 44, 2101-2101.	1.1	33
278	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16414.	3.7	33
279	Uptake of radiocesium by mushrooms. <i>Science of the Total Environment</i> , 1991, 106, 183-190.	8.0	32
280	Impedance study on the reactivity of gel polymer electrolytes towards a lithium electrode. <i>Journal of Power Sources</i> , 1996, 58, 139-144.	7.8	32
281	D2receptor binding in dopa-responsive dystonia. <i>Annals of Neurology</i> , 1998, 44, 758-762.	5.3	32
282	Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 327-328.	2.2	32
283	The efficacy of oral adenosine A _{2A} antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1383-1390.	2.8	32
284	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. <i>Frontiers in Neurology</i> , 2020, 11, 575975.	2.4	32
285	Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. <i>Npj Parkinson's Disease</i> , 2021, 7, 43.	5.3	32
286	Impairment of human dopaminergic neurons at different developmental stages by perfluoro-octanoic acid (PFOA) and differential human brain areas accumulation of perfluoroalkyl chemicals. <i>Environment International</i> , 2022, 158, 106982.	10.0	32
287	Relevance of sleep quality on caregiver burden in Parkinson's disease. <i>Neurological Sciences</i> , 2018, 39, 835-839.	1.9	31
288	Deep brain stimulation for monogenic Parkinson's disease: a systematic review. <i>Journal of Neurology</i> , 2020, 267, 883-897.	3.6	31

#	ARTICLE	IF	CITATIONS
289	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <sc>Movement Disorder Society</sc> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
290	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	3.9	31
291	Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. <i>Functional Neurology</i> , 2012, 27, 147-54.	1.3	31
292	Epitaxial growth and interface parameters of Si layers on GaAs(001) and AlAs(001) substrates. <i>Journal of Vacuum Science & Technology an Official Journal of the American Vacuum Society B, Microelectronics Processing and Phenomena</i> , 1991, 9, 2225.	1.6	30
293	Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. <i>Movement Disorders</i> , 2010, 25, 50-56.	3.9	30
294	Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. , 2016, 2016, 663-666.		30
295	Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 229-237.	2.6	30
296	Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. <i>Journal of Parkinson's Disease</i> , 2019, 9, 531-541.	2.8	30
297	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	2.4	30
298	Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence scale-8 items". <i>Neurological Sciences</i> , 2013, 34, 2015-2022.	1.9	29
299	Device-Aided Treatment Strategies in Advanced Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 453-474.	2.0	29
300	Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1203-1218.	2.4	29
301	Treatment with D-penicillamine improves dopamine D ₂ receptor binding and T ₂ signal intensity in de novo Wilson's disease. <i>Neurology</i> , 1994, 44, 1079-1079.	1.1	29
302	Synthesis of Mn spinels from different polymorphs of MnO ₂ . <i>Journal of Power Sources</i> , 1995, 56, 37-43.	7.8	28
303	Deep brain stimulation and its effect on sleep in Parkinson's disease. <i>Sleep Medicine</i> , 2004, 5, 211-214.	1.6	28
304	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , 2006, 21, 417-418.	3.9	28
305	The PRIAMO study: background, methods and recruitment. <i>Neurological Sciences</i> , 2008, 29, 61-65.	1.9	28
306	Secondary Parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]Fluorodopa. <i>Acta Neurologica Scandinavica</i> , 1996, 93, 387-392.	2.1	28

#	ARTICLE	IF	CITATIONS
307	Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. <i>Journal of Parkinson's Disease</i> , 2016, 6, 821-832.	2.8	28
308	Interhemispheric influences on area 19 of the cat. <i>Experimental Brain Research</i> , 1985, 59, 171-184.	1.5	27
309	Effect of partial Ga ³⁺ substitution for Mn ³⁺ in LiMn ₂ O ₄ on its behaviour as a cathode for Li cells. <i>Journal of Electroanalytical Chemistry</i> , 1996, 410, 115-118.	3.8	27
310	Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. <i>European Neuropsychopharmacology</i> , 2010, 20, 683-687.	0.7	27
311	Therapy-resistant symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 19-30.	2.8	27
312	Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale. <i>Npj Parkinson's Disease</i> , 2017, 3, 8.	5.3	27
313	Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. <i>Journal of Neural Transmission</i> , 2018, 125, 1131-1135.	2.8	27
314	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 21-26.	2.2	27
315	Band offsets and strain in CdTe-GaAs heterostructures. <i>Physical Review B</i> , 1993, 48, 8899-8910.	3.2	26
316	Relationship between pain and motor and non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 974-980.	3.3	26
317	Understanding and Treating Pain Syndromes in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 827-858.	2.0	26
318	The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 330.	3.4	26
319	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018, 21, 532-540.	0.8	26
320	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 73-81.	2.2	26
321	Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2303-2313.	3.9	26
322	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 186-194.	2.2	26
323	Infusion of nerve growth factor (NGF) into kitten visual cortex increases immunoreactivity for NGF, NGF receptors, and choline acetyltransferase in basal forebrain without affecting ocular dominance plasticity or column development. <i>Neuroscience</i> , 2001, 108, 569-585.	2.3	25
324	Dopamine agonist-based strategies in the treatment of Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 371-374.	1.9	25

#	ARTICLE	IF	CITATIONS
325	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , 2012, 33, 1319-1327.	1.9	25
326	Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α -synuclein gene. <i>Journal of Neurology</i> , 2012, 259, 165-167.	3.6	25
327	Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 217-221.	2.2	25
328	Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with freezing of gait. <i>Neurological Sciences</i> , 2015, 36, 1683-1686.	1.9	25
329	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018, 25, 1255-1261.	3.3	25
330	Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 1437-1445.	2.8	25
331	Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. <i>BMC Neurology</i> , 2021, 21, 332.	1.8	25
332	Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: A 1-H MRS study. <i>NeuroToxicology</i> , 2006, 27, 164-168.	3.0	24
333	A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. <i>Neurobiology of Disease</i> , 2008, 31, 102-109.	4.4	24
334	Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1160-1163.	2.2	24
335	Novel levodopa formulations in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 143-149.	2.8	24
336	Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2015, 355, 75-78.	0.6	24
337	Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1273-1277.	2.2	24
338	An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. <i>Advances in Therapy</i> , 2017, 34, 1741-1752.	2.9	24
339	Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. <i>Postgraduate Medicine</i> , 2019, 131, 509-522.	2.0	24
340	Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation. <i>Journal of Neural Transmission</i> , 2019, 126, 739-757.	2.8	24
341	Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients. <i>Brain Imaging and Behavior</i> , 2019, 13, 232-240.	2.1	24
342	Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza. <i>Neurological Sciences</i> , 2003, 24, s43-s44.	1.9	23

#	ARTICLE	IF	CITATIONS
343	Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. <i>Neurological Sciences</i> , 2008, 29, 387-388.	1.9	23
344	High-rate production of functional nanostructured films and devices by coupling flame spray pyrolysis with supersonic expansion. <i>Nanotechnology</i> , 2012, 23, 185603.	2.6	23
345	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013, 260, 1731-1742.	3.6	23
346	Improvement of dyskinesias with L-DOPA infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 451-458.	2.1	23
347	Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. <i>Neurological Sciences</i> , 2016, 37, 1785-1792.	1.9	23
348	Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial. <i>Trials</i> , 2018, 19, 492.	1.6	23
349	Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa/carbidopa intestinal gel. <i>European Journal of Neurology</i> , 2019, 26, 581.	3.3	23
350	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	5.3	23
351	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , 2022, 269, 1335-1352.	3.6	23
352	Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120008.	0.6	23
353	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 59-66.	2.2	23
354	Mapping subcortical extrarelay afferents onto primary somatosensory and visual areas in cats. <i>Journal of Comparative Neurology</i> , 1995, 362, 46-70.	1.6	22
355	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 108-115.	2.2	22
356	The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 1327-1333.	3.3	22
357	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021, 36, 681-689.	3.9	22
358	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 124-132.	2.2	22
359	Gender gap in deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.	5.3	22
360	European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. <i>European Journal of Neurology</i> , 2022, 29, 2580-2595.	3.3	22

#	ARTICLE	IF	CITATIONS
361	The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using ^{11}C -2- β -carbomethoxy-3- β -(4-fluorophenyl)-tropane in patients with movement disorders. <i>Nuclear Medicine Communications</i> , 2002, 23, 1047-1055.	1.1	21
362	What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. <i>Journal of Neural Transmission</i> , 2011, 118, 907-914.	2.8	21
363	Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. <i>Neurological Sciences</i> , 2013, 34, 621-627.	1.9	21
364	Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 685-695.	4.1	21
365	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 323-335.	2.8	21
366	Pharmacokinetic evaluation of pramipexole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1307-1314.	3.3	20
367	Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , 2021, 11, 773.	2.5	20
368	Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. <i>Journal of Neural Transmission</i> , 2004, 111, 497-509.	2.8	19
369	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 170-174.	1.5	19
370	Targeting pain in Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 1144-1145.	10.2	19
371	Cognitive impairment in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 1338-1339.	3.9	19
372	Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. <i>Neurodegenerative Disease Management</i> , 2019, 9, 39-46.	2.2	19
373	Comparison of self-reported symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects experiencing long-term olfactory dysfunction: a 6-month follow-up study. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1592-1595.	2.8	19
374	A procedure for the simultaneous visualization of two anterograde and different retrograde fluorescent tracers. <i>Journal of Neuroscience Methods</i> , 1991, 38, 183-191.	2.5	18
375	Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, 151-152.	1.9	18
376	Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. <i>European Journal of Neurology</i> , 2008, 15, 22-28.	3.3	18
377	Continuous dopaminergic delivery in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 305-308.	3.6	18
378	Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S120-S122.	2.2	18

#	ARTICLE	IF	CITATIONS
379	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	1.9	18
380	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012, 33, 689-694.	1.9	18
381	Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. <i>Lancet Neurology</i> , 2014, 13, 748-749.	10.2	18
382	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	2.2	18
383	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , 2015, 30, 1148-1149.	3.9	18
384	The Neural Correlates of Spatial and Object Working Memory in Elderly and Parkinson's Disease Subjects. <i>Behavioural Neurology</i> , 2015, 2015, 1-10.	2.1	18
385	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 113-117.	2.2	18
386	Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. <i>Journal of Neural Transmission</i> , 2020, 127, 323-330.	2.8	18
387	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021, 11, 623.	2.5	18
388	Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. <i>Movement Disorders</i> , 2022, 37, 182-189.	3.9	18
389	Lithiated MnO ₂ Phases as Cathodes for 3 V Li-ion Cells. <i>Journal of the Electrochemical Society</i> , 1997, 144, 1553-1559.	2.9	17
390	Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [¹¹ C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). <i>Neurological Sciences</i> , 2002, 23, s51-s52.	1.9	17
391	Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 319-329.	1.4	17
392	Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists. <i>Cardiovascular Therapeutics</i> , 2011, 29, 404-410.	2.5	17
393	Validation of the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS). <i>Neurological Sciences</i> , 2014, 35, 537-544.	1.9	17
394	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 57-64.	1.5	17
395	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1830-1841.	3.6	17
396	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. <i>Brain Communications</i> , 2021, 3, fcab180.	3.3	17

#	ARTICLE	IF	CITATIONS
397	Development and Validation of Automated ^{Magnetic Resonance} Parkinsonism Index 2.0 to Distinguish ^{Progressive Supranuclear Palsy} Parkinsonism From ^{Parkinson's Disease}. <i>Movement Disorders</i> , 2022, 37, 1272-1281.	3.9	17
398	Differences in binocular interactions between cortical areas 17 and 18 and superior colliculus of siamese cats. <i>Journal of Comparative Neurology</i> , 1981, 200, 597-611.	1.6	16
399	Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 297.	2.2	16
400	Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1130-1135.	2.2	16
401	Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 32-36.	2.2	16
402	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.	3.6	16
403	Benzodiazepine receptor binding in Huntington's disease: [¹¹ C]flumazenil uptake measured using positron emission tomography. <i>Annals of Neurology</i> , 2000, 47, 644-8.	5.3	16
404	Behavioral and electrophysiological effects of unilateral optic tract section in ordinary and siamese cats. <i>Journal of Comparative Neurology</i> , 1979, 185, 183-202.	1.6	15
405	Positron emission tomography in drug evaluation: Influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[¹⁸ F]fluoro-l-dopa in rhesus monkey. <i>Nuclear Medicine and Biology</i> , 1995, 22, 921-927.	0.6	15
406	Tremor UPDRS estimation in home environment. , 2016, 2016, 3642-3645.		15
407	A decision support system for Parkinson disease management: expert models for suggesting medication change. <i>Journal of Decision Systems</i> , 2018, 27, 164-172.	3.2	15
408	The impact of COVID-19 on palliative care for people with Parkinson's disease and response to future pandemics. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 615-623.	2.8	15
409	Immediate postoperative retention of visual discriminations following selective cortical lesions in the cat. <i>Behavioural Brain Research</i> , 1985, 17, 145-162.	2.2	14
410	Factors shaping the corpus callosum. <i>Journal of Comparative Neurology</i> , 2001, 433, 437-440.	1.6	14
411	[¹²³ I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in <i>PANK2</i> gene. <i>Neurology</i> , 2005, 64, 167-168.	1.1	14
412	Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. <i>European Journal of Neurology</i> , 2007, 14, 944-946.	3.3	14
413	The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 392-396.	1.9	14
414	MoSi ₂ laminate processed by tape casting: Microstructure and mechanical properties' investigation. <i>Intermetallics</i> , 2008, 16, 758-768.	3.9	14

#	ARTICLE	IF	CITATIONS
415	Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 2010, 33, 61-66.	0.7	14
416	Dopaminergic treatment and nonmotor features of Parkinson disease. <i>Neurology</i> , 2013, 80, 784-785.	1.1	14
417	“Gunslinger” gait: a new cause of unilaterally reduced arm swing. <i>BMJ, The</i> , 2015, 351, h6141.	6.0	14
418	Tuning AlAs-GaAs heterostructure properties by means of MBE-grown Si interface layers. <i>Surface Science</i> , 1991, 251-252, 82-86.	1.9	13
419	Unraveling depression in Parkinson’s disease. <i>European Journal of Neurology</i> , 2008, 15, 885-886.	3.3	13
420	Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease. <i>Journal of Movement Disorders</i> , 2009, 2, 4-9.	1.3	13
421	The Possible Clinical Predictors of Fatigue in Parkinson’s Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. <i>Parkinson’s Disease</i> , 2011, 2011, 1-7.	1.1	13
422	Validation of a home environment test battery for supporting assessments in advanced Parkinson’s disease. <i>Neurological Sciences</i> , 2012, 33, 831-838.	1.9	13
423	Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease. <i>Neurodegenerative Disease Management</i> , 2018, 8, 161-170.	2.2	13
424	Remote Evaluation of Parkinson’s Disease Using a Conventional Webcam and Artificial Intelligence. <i>Frontiers in Neurology</i> , 2021, 12, 742654.	2.4	13
425	Electrophysiological evidence for interhemispheric connections in the anterior ectosylvian sulcus in the cat. <i>Experimental Brain Research</i> , 1987, 66, 90-8.	1.5	12
426	Radiosynthesis of [¹¹ C]brofaromine, a potential tracer for imaging monoamine oxidase A. <i>Nuclear Medicine and Biology</i> , 1996, 23, 229-234.	0.6	12
427	Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 147-158.	2.2	12
428	New strategies in motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S446-S449.	2.2	12
429	The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 65-67.	1.4	12
430	Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson’s disease. <i>Neurological Sciences</i> , 2013, 34, 1751-1758.	1.9	12
431	Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence. <i>British Journal of Dermatology</i> , 2014, 170, 374-381.	1.5	12
432	Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 207-213.	2.8	12

#	ARTICLE	IF	CITATIONS
433	Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia. <i>Acta Neurochirurgica</i> , 2016, 158, 1789-1791.	1.7	12
434	Apomorphine infusion in advanced Parkinson disease. <i>Nature Reviews Neurology</i> , 2018, 14, 693-694.	10.1	12
435	Does the 5â€“2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5â€“2-1-positive patients in 7 countries. <i>BMC Neurology</i> , 2022, 22, 35.	1.8	12
436	Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation. <i>Journal of Neurosurgical Sciences</i> , 2003, 47, 40-6.	0.6	12
437	Indoor Exposure in a Region of Central Italy. <i>Radiation Protection Dosimetry</i> , 1984, 7, 271-274.	0.8	11
438	Cerebral 6-[18F]fluoro-l-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. <i>Brain Research</i> , 1997, 767, 45-54.	2.2	11
439	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. <i>European Journal of Neurology</i> , 2007, 14, 070206022829003-???	3.3	11
440	Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. <i>International Review of Neurobiology</i> , 2017, 133, 389-415.	2.0	11
441	Level I <sc>PDâ€“MCI</sc> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	1.5	11
442	Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 135-140.	1.9	10
443	Imaging for early differential diagnosis of parkinsonism. <i>Lancet Neurology</i> , The, 2010, 9, 130-131.	10.2	10
444	Exploring composites based on PPO blend as ablative thermal protection systems â€“ Part II: The role of equiaxial fillers. <i>Composite Structures</i> , 2012, 94, 1060-1066.	5.8	10
445	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013, 260, 1132-1135.	3.6	10
446	Can dopamine transporter imaging define early PD?. <i>Nature Reviews Neurology</i> , 2014, 10, 432-433.	10.1	10
447	Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinsonâ€™s Disease: A Pilot Study. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 205.	2.0	10
448	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , 2017, 8, 44-53.	1.3	10
449	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinsonâ€™s disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , 2020, 127, 875-879.	2.8	10
450	Geometrically Nonlinear Cantilever under Stochastic Loading Vectors. <i>Nonlinear Dynamics</i> , 2002, 28, 83-102.	5.2	9

#	ARTICLE	IF	CITATIONS
451	Sleep in Genetically Confirmed Pantothenate Kinase-Associated Neurodegeneration: A Video-Polysomnographic Study. <i>Parkinson's Disease</i> , 2010, 2010, 1-4.	1.1	9
452	Cortical visual evoked potentials recorded after optic tract near field stimulation during GPI-DBS in non-cooperative patients. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 119-122.	1.4	9
453	The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. <i>Neurological Sciences</i> , 2014, 35, 73-77.	1.9	9
454	<p>Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2899-2912.	2.2	9
455	Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. <i>Current Neuropharmacology</i> , 2021, 19, 1618-1639.	2.9	9
456	Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. <i>Clinical Neuropharmacology</i> , 1999, 22, 277-80.	0.7	9
457	Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. <i>Functional Neurology</i> , 2010, 25, 21-5.	1.3	9
458	Effects of Terguride in Patients with Huntington's Disease. <i>Clinical Neuropharmacology</i> , 1989, 12, 435-439.	0.7	8
459	Cerebral Metabolic Changes (¹⁸ F-FDG PET) during Selective Anterior Temporal Lobe Amobarbital Test. <i>European Neurology</i> , 1997, 38, 268-275.	1.4	8
460	Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019, 8, 159-166.	2.2	8
461	Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 266.	2.4	8
462	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2020, 127, 881-891.	2.8	8
463	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving a 2000mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.	1.1	8
464	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1309-1323.	2.8	8
465	Education on palliative care for Parkinson patients: development of the "Best care for people with late-stage Parkinson's disease" curriculum toolkit. <i>BMC Medical Education</i> , 2021, 21, 538.	2.4	8
466	MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. <i>Journal of Neurosurgical Sciences</i> , 2003, 47, 26-32.	0.6	8
467	Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Trial. <i>BMJ Open</i> , 2021, 15, e024444.	0.8	8
468	Clinical experience of tolcapone in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 380-382.	1.9	7

#	ARTICLE	IF	CITATIONS
469	Imaging evidence supports a link between essential tremor and Parkinson's disease. <i>Nuclear Medicine Communications</i> , 2009, 30, 93-94.	1.1	7
470	Cognitive Bizarreness in the Dream and Waking Mentation of Nonpsychotic Patients With Parkinsonâ€™s Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 395-400.	1.8	7
471	Low scan rate DSC study of the monoclinic-tetragonal transition in zirconia. <i>Thermochimica Acta</i> , 2011, 524, 18-22.	2.7	7
472	Pathological gambling in Parkinsonâ€™s disease: disease related or drug related?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 809-814.	2.8	7
473	Effects of rotigotine on Parkinson's disease-related sleep disturbances. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2571-2580.	1.8	7
474	Predicting rapid progression of Parkinson's Disease at baseline patients evaluation. , 2017, 2017, 3898-3901.		7
475	Prevalence of Extrapyrimal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. <i>Frontiers in Neurology</i> , 2020, 11, 593143.	2.4	7
476	Laboratoryâ€”Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <scp>MoDiMSA Study Group</scp>. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.	1.5	7
477	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregiversâ€”Study Protocol for a Multicentre, Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 673893.	2.4	7
478	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	2.4	7
479	The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 287-92.	2.2	7
480	Subthalamic deep brain stimulation in Parkinson's disease with <i>SNCA</i> mutations: Based on the followâ€”up to 10Â”years. <i>Brain and Behavior</i> , 2022, 12, e2503.	2.2	7
481	Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. <i>Journal of Neural Transmission Supplementum</i> , 1994, 43, 123-32.	0.5	7
482	Safinamide in the treatment pathway of Parkinsonâ€™s Disease: a European Delphi Consensus. <i>Npj Parkinson's Disease</i> , 2022, 8, 17.	5.3	7
483	BILATERAL SUBTHALAMIC DEEP BRAIN STIMULATION IN A PATIENT WITH PARKINSON'S DISEASE WHO HAD PREVIOUSLY UNDERGONE THALAMOTOMY AND AUTOLOGOUS ADRENAL GRAFTING IN THE CAUDATE NUCLEUS. <i>Neurosurgery</i> , 2006, 59, E1140-E1140.	1.1	6
484	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
485	Clinical variables associated with treatment changes in Parkinsonâ€™s disease: results from the longitudinal phase of the REASON study. <i>Neurological Sciences</i> , 2015, 36, 935-943.	1.9	6
486	tDCS effect on cognitive performance in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1253-1254.	3.9	6

#	ARTICLE	IF	CITATIONS
487	Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116411.	0.6	6
488	Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 165-177.	2.2	6
489	Movement perception of the tonic vibration reflex is abnormal in functional limb weakness. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 1-6.	2.2	6
490	Reduced Effective Connectivity in the Motor Cortex in Parkinson's Disease. <i>Brain Sciences</i> , 2021, 11, 1200.	2.3	6
491	Efficacy, safety and patient's quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson's disease in Romania: Results from GLORIA observational study. <i>Romanian Journal of Neurology/ Revista Romana De Neurologie</i> , 2020, 19, 27-35.	0.1	6
492	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries. <i>Neurology and Therapy</i> , 2022, 11, 303-318.	3.2	6
493	Side Effects of the Catechol-O-Methyl-Transferase Inhibitor Ro 407592 in Rabbits. <i>Clinical Neuropharmacology</i> , 1994, 17, 270-276.	0.7	5
494	Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes. <i>Movement Disorders</i> , 2012, 27, 1552-1555.	3.9	5
495	Is there room for new non-dopaminergic treatments in Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2013, 120, 349-352.	2.8	5
496	Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights. <i>European Journal of Neurology</i> , 2016, 23, 435-436.	3.3	5
497	DBS for Parkinson's disease with behavioural disturbances. <i>Lancet Neurology</i> , The, 2018, 17, 195-197.	10.2	5
498	Health care for chronic neurological patients after COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 562-563.	10.2	5
499	Comment on "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis". <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 852-852.	1.9	5
500	Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-in Parkinson's disease-Cognition (SCOPA-Cog). <i>Functional Neurology</i> , 2013, 28, 121-5.	1.3	5
501	Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. <i>Neurology and Therapy</i> , 2022, 11, 1409-1425.	3.2	5
502	Mössbauer study of the Pb ₁₂₅ Sn ¹²⁵ Te system. <i>Physica Status Solidi (B): Basic Research</i> , 1982, 114, 585-588.	1.5	4
503	Radon and radon daughter evaluation in a natural radioactivity survey indoors. <i>Science of the Total Environment</i> , 1985, 45, 373-380.	8.0	4
504	Daytime somnolence and night sleep disturbances in Parkinson's disease: background and future treatment prospective. <i>Neurological Sciences</i> , 2007, 28, S6-S8.	1.9	4

#	ARTICLE	IF	CITATIONS
505	Single photon-emission computed tomography imaging in early Parkinson's disease. Expert Review of Neurotherapeutics, 2008, 8, 1853-1864.	2.8	4
506	Rapid onset of efficacy of rasagiline in early Parkinson's disease. Neurological Sciences, 2013, 34, 2007-2013.	1.9	4
507	Brain Networks of Motor Behavior Assessed by Principal Component Analysis. , 1998, , 165-172.		4
508	Effect of Intensive Rehabilitation Program in Thermal Water on a Group of People with Parkinson's Disease: A Retrospective Longitudinal Study. Healthcare (Switzerland), 2022, 10, 368.	2.0	4
509	Quantification of Brain β -Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study. Frontiers in Neurology, 2021, 12, 760518.	2.4	4
510	Antiphospholipid-Related Chorea: Two Case Reports and Role of Metabolic Imaging. Movement Disorders Clinical Practice, 2022, 9, 516-521.	1.5	4
511	Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. Journal of Personalized Medicine, 2022, 12, 813.	2.5	4
512	Mössbauer studies of the Umbria archeological clays. Hyperfine Interactions, 1986, 29, 1133-1136.	0.5	3
513	The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) – an interim analysis of a multicentre study of the patient's perspective. Parkinsonism and Related Disorders, 2016, 22, e41.	2.2	3
514	Reply to: "Concerns Raised by Publication of Antonini et al., "Outcome of Parkinson Disease Patients Affected by COVID-19". Movement Disorders, 2020, 35, 1298-1298.	3.9	3
515	Predictors of Response for "Off" Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry. Frontiers in Neurology, 2020, 11, 419.	2.4	3
516	Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population. Neurological Sciences, 2020, 41, 2929-2937.	1.9	3
517	Oscillatory EEG-TMS Reactivity in Parkinson Disease. Journal of Clinical Neurophysiology, 2023, 40, 263-268.	1.7	3
518	Non-motor Symptoms in Parkinson's Disease. European Neurological Review, 2009, 4, 25.	0.5	3
519	Efficacy of opicapone in different treatment regimens in Parkinson's disease patients with motor fluctuations. Parkinsonism and Related Disorders, 2020, 79, e64-e65.	2.2	3
520	Mössbauer Study of the Pb-Sn Te System. Physica Status Solidi (B): Basic Research, 1983, 120, K15.	1.5	2
521	Detectability by photoacoustic spectroscopy of x-ray-induced ethylene emission in mice breath. , 2003, , .		2
522	DN1 ECONOMIC EVALUATION OF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY. Value in Health, 2005, 8, A14.	0.3	2

#	ARTICLE	IF	CITATIONS
523	2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S110.	2.2	2
524	Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa" sparing Regimens. <i>Movement Disorders</i> , 2019, 34, 1930-1931.	3.9	2
525	Patient-centred management of Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 887-888.	10.2	2
526	Dyskinesia Matters: But Not as Much as It Used to. <i>Movement Disorders</i> , 2020, 35, 900-901.	3.9	2
527	Evaluation of cefepime kinetic variables and milk production volume in goats. <i>Arquivo Brasileiro De Medicina Veterinaria E Zootecnia</i> , 2004, 56, 116-118.	0.4	2
528	Repetitive transcranial magnetic stimulation in the treatment of dystonia. , 2012, , 501-511.		2
529	Alpha-synuclein pathology and enteric glia in advanced Parkinson's disease: A study from gastrointestinal biopsies. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119460.	0.6	2
530	Fractal Analysis of Lower Back Acceleration Profiles in balance tasks. , 2021, 2021, 7381-7384.		2
531	Action Selection and Motor Decision Making: Insights from Transcranial Magnetic Stimulation. <i>Brain Sciences</i> , 2022, 12, 639.	2.3	2
532	Morbo di Parkinson, esposizione a sostanze tossiche e nuclei della base Uno studio mediante spettroscopia protonica a risonanza magnetica. <i>The Neuroradiology Journal</i> , 2001, 14, 47-48.	0.1	1
533	Channeling-based collimators for generation of microbeams produced by silicon micromachining technology. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2006, 252, 11-15.	1.4	1
534	1.018 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [¹²³ I]β-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S32.	2.2	1
535	Bioactive Sulforaphane from in vitro Propagated Brassica Seedlings. <i>Engineering in Life Sciences</i> , 2007, 7, 275-277.	3.6	1
536	P1.229 Improvement of motor and non-motor symptoms after switching from oral therapy to continuous duodenal levodopa infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S88.	2.2	1
537	The conundrum of neuroprotection in Parkinson's disease. <i>Lancet Neurology</i> , The, 2011, 10, 396-397.	10.2	1
538	Movement disorders: towards new therapies in Parkinson's disease. <i>Lancet Neurology</i> , The, 2012, 11, 7-8.	10.2	1
539	Dopaminergic treatment and nonmotor features of Parkinson disease: The horse lives. <i>Neurology</i> , 2013, 81, 854-855.	1.1	1
540	Design and Development of a Mobile Application to Explore Cognitive Skills in Parkinson's Disease Patients. <i>IFMBE Proceedings</i> , 2016, , 1150-1155.	0.3	1

#	ARTICLE	IF	CITATIONS
541	Mining motor symptoms UPDRS data of Parkinson's disease patients for the development of Hoehn and Yahr estimation decision support system. , 2017, , .		1
542	Baseline characteristics that influence "coeff" time improvement in levodopa-carbidopa intestinal gel-treated advanced Parkinson's disease patients in the GLORIA registry. Journal of the Neurological Sciences, 2017, 381, 187.	0.6	1
543	A decision support system based on rapid progression rules to enhance baseline evaluation of Parkinson's disease patients. , 2018, , .		1
544	Reply: Dynamic functional connectivity changes in Lewy body disease. Brain, 2019, 142, e69-e69.	7.6	1
545	Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 972.	2.4	1
546	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. Alzheimer's and Dementia, 2020, 16, e043593.	0.8	1
547	TaSCA, an Agile Survey on Chemosensory Impairments for Self-Monitoring of COVID-19 Patients: A Pilot Study. Frontiers in Neurology, 2021, 12, 633574.	2.4	1
548	Opicapone's added benefit as a first-line adjunctive therapy to levodopa and when used promptly for motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, e71-e72.	2.2	1
549	High Energy Resolution Photoemission Beam Line at ELETTRA. Acta Physica Polonica A, 1994, 86, 487-495.	0.5	1
550	The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study. Journal of the Neurological Sciences, 2021, 429, 119422.	0.6	1
551	Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat. , 1987, , 349-366.		1
552	Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. Journal of Neurosurgical Sciences, 2017, 62, 103-105.	0.6	1
553	Neurocognitive correlates of numerical abilities in Parkinson's disease. Neurological Sciences, 2022, 43, 5313-5322.	1.9	1
554	Functional organization of the anterior ectosylvian cortex in the cat. Behavioural Brain Research, 1987, 26, 230-230.	2.2	0
555	Voluntary allocation of visual attention to foveal and extrafoveal sites. Behavioural Brain Research, 1987, 26, 240-241.	2.2	0
556	A calibration bench for electro-optical characterization of CCD sensors. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 1993, 326, 150-153.	1.6	0
557	PNL16 THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY. Value in Health, 2005, 8, A133.	0.3	0
558	<title>Fabrication of devices for channeling-based high-energy micro-beams</title>. , 2007, , .		0

#	ARTICLE	IF	CITATIONS
559	<title>Silicon micromachining techniques as a tool to fabricate channeling-based devices</title>. , 2007, , .		0
560	1.164 Psychiatric symptoms in Parkinson's disease: An assessment in 486 Italian patients. Parkinsonism and Related Disorders, 2007, 13, S50.	2.2	0
561	1.166 Diagnosis of personality structure and cognition in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S50-S51.	2.2	0
562	2.214 Tolcapone treatment fluctuating patients with Parkinson's disease who did not benefit from entacapone. Parkinsonism and Related Disorders, 2007, 13, S101.	2.2	0
563	2.220 Duodenal levodopa infusion for advanced Parkinson's disease: 24-month treatment outcome. Parkinsonism and Related Disorders, 2007, 13, S103.	2.2	0
564	2.262 Adherence to antiparkinson medication in a multi-centre European study.. Parkinsonism and Related Disorders, 2007, 13, S115.	2.2	0
565	What you always wanted to know about â€¦ The newest therapeutical strategies. Parkinsonism and Related Disorders, 2007, 13, S152.	2.2	0
566	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2008, 14, 266-267.	2.2	0
567	Spect imaging biomarkers. Journal of the Neurological Sciences, 2009, 283, 268.	0.6	0
568	O.058 Will continuous dopamine stimulation prevent motor complications?. Parkinsonism and Related Disorders, 2009, 15, S15.	2.2	0
569	SPECT Imaging in Movement Disorders. , 2010, , 140-147.		0
570	Bladder Dysfunction. , 2011, , 67-72.		0
571	Movement disorders in multiple sclerosis. , 0, , 268-278.		0
572	The Face Behind the Mask: Can Imaging Help Early Parkinson Diagnosis?. Movement Disorders Clinical Practice, 2015, 2, 1-2.	1.5	0
573	Anatomical profile of cognitive impairment in MSA. Parkinsonism and Related Disorders, 2016, 22, e118.	2.2	0
574	503 BRAF-V600 Mutation discordance in Primary and Metastatic Melanoma. Journal of Investigative Dermatology, 2016, 136, S246.	0.7	0
575	494 Heterogeneous mutational status of melanomas in multiple primary melanoma patients. Journal of Investigative Dermatology, 2016, 136, S244.	0.7	0
576	Levodopa-carbidopa intestinal gel treatment in patients with <10 years of Parkinson's disease: GLORIA registry interim results. Parkinsonism and Related Disorders, 2016, 22, e93-e94.	2.2	0

#	ARTICLE	IF	CITATIONS
577	Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: GLORIA long-term registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e96-e97.	2.2	0
578	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e97-e98.	2.2	0
579	Multicenter experience of mixed deep brain stimulation implants for movement disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e105-e106.	2.2	0
580	Determination of minimal important difference thresholds for Parkinson's disease Questionnaire-39 in advanced Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e18-e19.	2.2	0
581	Non-motor symptoms (nms) improvement is correlated with baseline nms burden and improved quality of life (QoL) in levodopa-carbidopa intestinal gel (LCIG) treated parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2017, 381, 98.	0.6	0
582	Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 211.	0.6	0
583	Utilization of COMT inhibitors, dopamine agonists, and MAO-B inhibitors with levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: Summary of phase 3 and real-world studies. <i>Journal of the Neurological Sciences</i> , 2019, 405, 29-30.	0.6	0
584	Efficacy of opicapone in Parkinson's disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 192.	0.6	0
585	Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 203.	0.6	0
586	New routes of dopaminergic drug delivery in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 105-106.	10.2	0
587	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042969.	0.8	0
588	Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". <i>Movement Disorders</i> , 2021, 36, 2208-2209.	3.9	0
589	Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119438.	0.6	0
590	Challenges in advanced treatments in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117949.	0.6	0
591	Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119450.	0.6	0
592	Adoption (early levodopa with opicapone in Parkinson's patients with motor fluctuations) study in Parkinson's disease: Design and rationale of a randomized prospective, open-label exploratory trial. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119423.	0.6	0
593	The ocean (opicapone effect on motor fluctuations and associated pain) study in Parkinson's disease: Design and rationale of a randomized double-blind placebo-controlled trial. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119424.	0.6	0
594	Parkinsonian Tremor. , 2011, , 64-72.		0

#	ARTICLE	IF	CITATIONS
595	Role of Callosal Connections in the Representation of the Visual Field in the Primary Visual Cortex of the Cat. , 1987, , 349-366.		0
596	Lisuride and [C-11]-Raclopride Interaction at the D2 Receptor Site. , 1995, , 205-214.		0
597	Neutral Amino Acids Influence [18 F]Fluorodopa Quantification 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 379-385.		0
598	Early Compensatory Mechanisms in <sc>LRRK2</sc> Mutation Carriers. Movement Disorders, 2022, 37, 662-663.	3.9	0
599	Opicapone as first-line adjunctive levodopa treatment in Parkinson's disease patients with motor fluctuations: BIPARK-I and II combined post-hoc analysis. Parkinsonism and Related Disorders, 2020, 79, e63.	2.2	0
600	Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study. Parkinsonism and Related Disorders, 2020, 79, e86.	2.2	0
601	Content validity of MANAGE-PD tool: Real-world evidence from PD patients in G7 countries. Parkinsonism and Related Disorders, 2020, 79, e46-e47.	2.2	0
602	Continuous dopaminergic stimulation in the management of complicated Parkinson's disease. Mount Sinai Journal of Medicine, 1988, 55, 62-6.	1.9	0
603	Spotlight on non-motor symptoms and Covid-19. International Review of Neurobiology, 2022, , .	2.0	0